Ascendis Pharma A/S (NASDAQ:ASND) Director Buys $492,660.00 in Stock

Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime acquired 2,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares in the company, valued at approximately $714,357. This trade represents a 222.22% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Jean Jacques Bienaime also recently made the following trade(s):

• On Tuesday, May 26th, Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock. The shares were bought at an average price of $237.80 per share, with a total value of $95,120.00.

Ascendis Pharma A/S Price Performance

ASND stock traded up $1.45 during trading on Tuesday, hitting $248.85. The company had a trading volume of 452,630 shares, compared to its average volume of 528,844. The company has a fifty day moving average price of $251.15 and a two-hundred day moving average price of $237.51. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The company has a market cap of $15.52 billion, a P/E ratio of 19.31 and a beta of 0.39. Ascendis Pharma A/S has a fifty-two week low of $186.05 and a fifty-two week high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. The company had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Equities research analysts expect that Ascendis Pharma A/S will post 4.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cetera Investment Advisers bought a new position in shares of Ascendis Pharma A/S in the second quarter worth about $552,000. Rhumbline Advisers grew its stake in shares of Ascendis Pharma A/S by 4.0% during the second quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 55 shares during the last quarter. Daiwa Securities Group Inc. grew its stake in shares of Ascendis Pharma A/S by 66.2% during the second quarter. Daiwa Securities Group Inc. now owns 3,737 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 1,488 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Ascendis Pharma A/S by 83.4% in the second quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock valued at $34,700,000 after purchasing an additional 91,412 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of Ascendis Pharma A/S in the second quarter valued at approximately $897,000.

Wall Street Analyst Weigh In

ASND has been the topic of a number of recent analyst reports. Evercore restated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Barclays dropped their price objective on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a report on Friday. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday. Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a report on Tuesday, June 9th. Finally, Royal Bank Of Canada increased their price target on Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $300.33.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.